Tianyi Medical Private Equity Fund has led a RMB250 million investment round in Asymchem Laboratories (Tianjin) Co, Ltd. (Asymchem). Tianyi Medical Private Equity Fund, a joint venture of Infinity Group and Tianjin Venture Capital (TJVC), focuses on investments in the biomedical industry. Tianyi Medical Private Equity Fund and TJVC co-invested RMB90 million.
Asymchem is an international pharmaceutical company which provides professional biotechnology services to help pharmaceutical companies to shorten the development period of new products and speed up the launching of new drugs. The main business of Asymchem is to develop, optimise, and manufacture raw materials, API as well as to prepare products according to cGMP requirements, and to provide clinical research medicines and marketed medicine according to US and EU standards. Asymchem has established five companies and is the biggest pharmaceutical company providing CMO services in China.
The investment announced today will be used to help Asymchem increase its production capability, undertake more orders from international pharmaceutical companies, improve Asymchem’s general competitive capabilities, strengthen the merger of the Chinese and international markets, and promote the interconnection of the pharmaceutical industry in China with that of the international pharmaceutical industry.
"Asymchem is one of the largest and most respected pharmaceutical manufactures in China and a ‘one stop shop’ and strategic partner for several multi-national pharmaceutical companies. Under the impressive leadership of Chairman and CEO Dr. Hao Hong and his very professional management team, the company has continuously shown steady growth in revenues, even in challenging times and a competitive arena. We are very happy to invest in Asymchem as we see a bright future for this company," says Dr Bella Ohana, Managing Director of Life Science at Infinity Group.
